Advancedcell biology
Amyloid Diseases: When Proteins Aggregate
Overview
Many unrelated proteins can misfold into amyloid fibrils — highly ordered cross-beta aggregates that damage tissues. This lesson covers amyloid structure, the major amyloid diseases, and therapeutic strategies.
Learning objectives
- Describe amyloid fibril structure
- Explain the amyloid hypothesis of Alzheimer's
- Distinguish major amyloid diseases
- Evaluate therapeutic approaches
What is amyloid?
Amyloid fibrils are unbranched protein aggregates with a cross-beta structure: beta-strands run perpendicular to the fibril axis. They bind Congo red (apple-green birefringence) and thioflavin T — diagnostic hallmarks.
Cross-beta fibrils + Congo red birefringence = amyloid, regardless of the protein.
Alzheimer's disease
Amyloid-beta plaques and tau tangles characterize Alzheimer's. The amyloid hypothesis holds that Aβ aggregation initiates the cascade; genetics (APP, presenilin mutations) strongly support it. Anti-amyloid antibodies (lecanemab) modestly slow decline.
APP/presenilin mutations → early-onset Alzheimer's: the strongest genetic evidence for the amyloid hypothesis.
Other amyloid diseases
Parkinson's (alpha-synuclein Lewy bodies), Huntington's (polyglutamine), type 2 diabetes (amylin in pancreas), systemic AL amyloidosis (immunoglobulin light chains in organs).
Same fibril architecture, different proteins, different organs — amyloid is a fold, not a specific protein.
Oligomers vs. fibrils
Growing evidence implicates small soluble oligomers — not the large fibrils — as the most toxic species. Fibrils may even be protective sinks sequestering toxic oligomers.
Toxicity likely comes from oligomers; fibrils may be the tombstones, not the killers.
Therapeutic strategies
Anti-aggregation antibodies, BACE inhibitors (reduce Aβ production), chaperone boosters, and early-intervention trials. Success has been modest — highlighting the need to treat before symptoms.
Lecanemab/donanemab slow decline ~25-35% in early Alzheimer's — proof of concept, not cure.
Key points
- Amyloid = cross-beta fibrils
- Congo red gives apple-green birefringence
- Aβ plaques define Alzheimer's
- Oligomers likely most toxic
- Many proteins can form amyloid
Common misconceptions
✓ Truth: Soluble oligomers correlate better with toxicity; plaques may partly be protective sequestration.
✓ Truth: Light chains, amylin, transthyretin and others form systemic amyloid in organs throughout the body.
Practice questions
Q1. Amyloid is diagnosed histologically by:
- Congo red staining with apple-green birefringence
- Gram staining
- Silver staining only
- H&E always
Congo red binding with characteristic birefringence under polarized light is the diagnostic gold standard.
Q2. In Alzheimer's, amyloid-beta derives from:
- APP processing by secretases
- Tau protein
- Alpha-synuclein
- Prion protein
Beta- and gamma-secretase cleave amyloid precursor protein to release Aβ peptides.
Q3. Systemic AL amyloidosis involves aggregation of:
- Immunoglobulin light chains
- Insulin
- Hemoglobin
- Collagen
Plasma cell disorders overproduce light chains that deposit as amyloid in kidneys, heart, and other organs.
Click a question to reveal the answer and explanation.
Frequently asked questions
What structural feature defines amyloid fibrils?
Cross-beta structure: beta-strands oriented perpendicular to the fibril axis, forming extremely stable hydrogen-bonded sheets. This common architecture binds Congo red and thioflavin T.
What is the amyloid hypothesis of Alzheimer's?
That accumulation of amyloid-beta initiates a cascade (tau tangles, inflammation, synaptic loss) causing dementia. Supported by APP/presenilin genetics and modest benefits of anti-amyloid antibodies.
Why might oligomers be more toxic than fibrils?
Small soluble oligomers expose hydrophobic surfaces that disrupt membranes and synapses, while large fibrils bury these surfaces — fibrils may sequester toxic species rather than cause damage directly.